GENETIC FACTORS AND PROSTATE CANCER (INFLUENCE OF SINGLE NUCLEOTIDE POLYMORPHISMS C825T IN GENE GNB3 AND D85Y IN GENE UGT2B15)
Abstract
Background. In Slovenia, incidence of prostate cancer (CaP) is approximately half of incidence in neighbouring Austria. With ageing of population and increasing awareness, incidence is increasing. Treatment of CaP can drastically decrease quality of life and course of disease is not possible to predict. As main risk factor for CaP is heredity, one way of looking for prognostic factors is evaluation of influence of single nucleotide polymorphisms (SNPs).
Methods. DNA was isolated from peripheral blood of 86 patients with histologically proven prostate cancer and 178 controls. Polymorphisms D85Y in gene UGT2B15 and C825T in gene GNB3 were evaluated with RFLP. Frequencies of alleles were compared between controls and patients and between patients stratified according to the Gleason score (less than 7 and 7 or more).
Results. D85Y: patients: 23% DD, 49% DY, controls 16% DD, 52% DY (NS). In patients with Gleason score 7 or more frequency of DD was 33% and with Gleason score less than 7 15% (risk ratio for DD 2.97, p = 0.041). C825T: patients: 14% TT, 44% CT, controls 8% TT, 46% CT (NS).
Conclusions. Although study did not confirm influence of evaluated polymorphisms on risk for developing prostate cancer, we identified significantly higher frequency of D allele of polymorphism D85Y in subgroup of patients with poorly differentiated CaP. This polymorphism could become one of the prognostic factors in CaP.
Downloads
References
Bahnson RR. Improving prostate cancer detection. J Urol 2000; 164: 405–5.
Ferlay J, Bray F, Sankila R, Parkin DM. EUCAN: Cancer incidence, mortality and prevalence in the European Union. IARC Cancer Base No. 4. Lyon: IARCPress, 2001.
Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5. Lyon: IARCPress, 2001.
Incidenca raka v Sloveniji 1995. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1998.
Incidenca raka v Sloveniji 2000. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003.
Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990; 17: 337–47.
Chakravarti A. To a future of genetic medicine. Nature 2001; 409: 822–3.
Latil AG, Azzouzi R, Cancel GS et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001; 92: 1130–7.
MacLeod SL, Nowell S, Plaxco J, Lang NP. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 2000; 7: 777–82.
Hum DW, Belanger A, Levesque E et al. Characterization of UDP-glucuronosyltransferases active on steroid hormones. J Steroid Biochem Mol Biol 1999; 69: 413–23.
Levesque E, Beaulieu M, Green MD, Tephly TR, Belanger A, Hum DW. Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997; 7: 317–25.
Siffert W, Forster P, Jockel KH, Mvere DA, Brinkmann B, Naber C et al. Worldwide ethnic distribution of the G protein beta 3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999; 10: 1921–30.
Kue PF, Daaka Y. Essential role for G proteins in prostate cancer cell growth and signaling. J Urol 2000; 164: 2162–7.
Xia C, Ma W, Wang F, Hua Sb, Liu M. Identification of a prostate-specific Gprotein coupled receptor in prostate cancer. Oncogene 2001; 20: 5903–7.
Siffert W, Naber C, Walla M, Ritz E. G protein beta 3 subunit 825T allele and its potential association with obesity in hypertensive individuals. J Hypertens 1999; 17: 1095–8.
Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 2001; 11: 534–42.
Babaian RJ, Fritsche H, Ayala A et al. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. Urology 2000; 56: 1000–6.
Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781–9.
Ward JF, Zincke H. Radical prostatectomy for the patient with locally advanced prostate cancer. Curr Urol Rep 2003; 4: 196–204.
Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 2002; 168: 1008–12.
Tewari A, Narayan P. Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks. J Urol 1998; 160: 430–6.
Iversen P. Editorial: Quality of life issues for patients with prostate cancer. J Urol 2001; 166: 2291–2.
Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491–8.
Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225–9.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
